Laboratory support of ABO antibody monitoring for ABO-incompatible solid organ transplantation.

The accurate measurement of ABO antibodies is essential for successful ABO-incompatible solid organ transplantation. Titration using two-fold dilution is considered a standard method and is applied in most laboratories. However, this titration method has inherent limitations, including differences in methods between laboratories, a lack of standardization, its semiquantitative nature, and the difficulty of considering the results to be representative of the in vivo activity of ABO antibodies. Various measurement methods other than titration have been developed, and new methods continue to be introduced. Physicians and laboratory specialists who are involved in ABO-incompatible solid organ transplantation need to fully understand these methods for optimal patient management.

INTRODUCTION

Unlike other common blood groups, ABO antigens are expressed not only on red blood cells, but also in many other tissues. In particular, ABO antigens are present in vascular endothelial cells; therefore, ABO-incompatible solid organ transplantation was contraindicated for a long time. However, with the development of various desensitization and immunosuppression modalities, ABO-incompatible solid organ transplantation is no longer an absolute contraindication [1]. According to data from the Center for Korean Network for Organ Sharing, 26.4% of living donor kidney and liver transplantations performed in Korea in 2019 were ABO-incompatible [2].

For ABO-incompatible solid organ transplantation, the level of ABO antibodies should be reduced below a specific threshold through desensitization using rituximab administration and an antibody removal method such as plasmapheresis before surgery. Additional treatment is determined by monitoring whether ABO antibodies increase after surgery [3]. The specific protocols vary across laboratories, but accurate ABO antibody measurements play a decisive role in establishing the treatment plan regardless of the protocol followed. However, ABO antibody tests are not standardized and have significant variations between laboratories [4,5]. This review covers the various methods of ABO antibody measurements for ABO-incompatible solid organ transplantation.

ABO ANTIBODIES

ABO antibodies naturally occur and differ from the known adaptive immune response. Unlike immune antibodies, which develop as immunoglobulin M (IgM) before switching to immunoglobulin G (IgG) when exposed to antigens, ABO antibodies often persist as IgM. In particular, most type A and type B ABO antibodies are IgM [6]. IgG antibodies are found relatively frequently in type O, and the IgG2 subclass is the main component [7]. Institutions have different protocols regarding which antibodies are monitored for ABO-incompatible transplantation. As mentioned above, the main component of ABO antibodies is IgM, and the IgG antibodies that are present often belong to the IgG2 subclass, which has a low complement activation capacity. A recent study reported that ABO-incompatible transplantation could be successfully conducted by monitoring IgM isoagglutinin titers [8]. However, another study reported the clinical significance of anti-A/B IgG titers in ABO-incompatible transplantation [9]. Further studies are needed to clarify this issue.

At birth, there is only a small amount of ABO antibodies, which derive from the placental transfer of maternal IgG antibodies, but ABO antibodies begin to develop at 3–6 months after birth and reach adult levels at the age of 5–10 years. This provides a rationale for ABO-incompatible heart transplantation in infants [10].

It is understood that the cause of naturally occurring ABO antibodies without exposure to ABO antigens is due to cross-reaction to similar antigens present in the environment, especially bacteria. Hence, the ABO antibody titer is well-known to be elevated when exposed to bacterial antigens [11].

ABO ANTIBODY TITRATION

Blood group antibodies are conventionally measured as titers using the two-fold dilution method. Titration is a method wherein the amount of antibodies is indirectly expressed as the reciprocal of the endpoint titer obtained by serially diluting the serum. The titer endpoint that shows agglutination is interpreted as the isoagglutinin titer (Fig. 1). Two representative methods for the titration of anti-A and anti-B antibodies are the tube method and the column agglutination technique (CAT).

Fig. 1

A schematic description of isoagglutinin titer measurement using the conventional tube method. The isoagglutinin titer is determined as the endpoint that shows agglutination with two-fold dilution. Each laboratory sets its own cutoff (trace or 1+) according to the titration protocol.

The accurate measurement of anti-D antibody titers in RhD-negative mothers has been critical for the diagnosis and management of hemolytic disease of the fetus and newborn (HDFN). For HDFN, titration has been widely used for a long time. As ABO-incompatible solid organ transplantation became possible, the necessity and demand for measurements of anti-A and anti-B antibodies increased. Titration using two-fold dilution is widely performed for the measurement of ABO antibodies in many clinical laboratories because it has a long history, practitioners have accumulated related experience, and it does not deviate from the basic framework of other transfusion-related tests. However, titration has several inherent limitations. It has not been standardized, and there are significant interobserver and interlaboratory variations [12,13]. Titration techniques are different among laboratories in terms of whether they use the tube or CAT method, as well as according to whether they measure IgM or IgG [7,14]. The semiquantitative nature of titration is another disadvantage for clinical usage. The selection of reagent cells is another aspect that can influence the standardization of titration. Dosage effects for some blood groups, including Rh, are a well-known phenomenon, although relatively little is known regarding ABO antigens. Further research is needed for the selection of appropriate reagent cells for ABO antibody titration standardization. Lastly, like other techniques that have been developed to date, titration gives information about the antigen-antibody binding reaction, but this is insufficient to tell us what might happen in vivo.

According to the College of American Pathologists (CAP), which is a representative external quality assessment organization, external quality assessment is used for the titration of ABO antibodies and anti-D antibodies [15]. These processes vary depending on the reagent cell, the diluent, the presence of anti-human globulin or dithiothreitol (DTT), the incubation time, and the reaction temperature. In order to reduce variations and standardize these methods, the CAP proposed a uniform procedure in 2008 [16]. It aims to ensure that the results are consistent regardless of the laboratory through the use of specific suggested protocols for reagent cells, diluents, reaction conditions, and reagents for titration testing using the tube method or CAT. However, it was found that these protocols did not actually help to reduce the variation among laboratories [12]. Thus, the mode±2 titers is set as an acceptable range in external quality assessments of the CAP [15]. Thus, laboratories that report results with a difference of up to four titers for the same specimen may all receive acceptable results from external quality assessments. Thus, it is challenging to compare titer results among laboratories. Each laboratory should set its own cutoff for titers in the ABO-incompatible transplantation protocol. The recent development of antibody titration conducted by automated blood type analyzers is expected to enhance the uniformity of test results in the future.

NOVEL METHODS FOR ABO ANTIBODY MEASUREMENTS

Flow Cytometry

Some reports have described ABO antibody measurement using flow cytometry [17-20]. This method has the advantage of classifying the immunoglobulin type and subclass depending on which antibody is used as the secondary antibody. Moreover, there is no need for DTT treatment to remove IgM, and multiple types of antibodies can be analyzed simultaneously using various combinations of antibodies. However, this method is also not standardized, and although the fluorescent intensity value is expressed, it is not quantitative data. In addition, special equipment and skilled personnel are required for the test, and there are limitations in using it for routine tests due to cost and time.

Complement-Dependent Cytotoxicity

The authors recently developed and published an ABO antibody measurement method that applies the complement-dependent cytotoxicity method using a principle similar to that of the human leukocyte antigen antibody test [21] (Fig. 2). This method was developed based on the fact that the in vivo pathological process that causes problems with ABO antibodies during ABO-incompatible transplantation begins with complement activation [5,22]. The advantage of this method is that quantitative data can be obtained by establishing 0% and 100% hemolysis control, and in vivo activity can be estimated regardless of immunoglobulin type or subclass. However, since this is still a newly developed method, it has not yet been validated on a large scale. Furthermore, since this test involves several manual procedures, it is labor-intensive and time-consuming. The enzyme-linked immunosorbent assay method was also recently introduced for the measurement of ABO antibodies, but it has not yet been widely distributed [22].

Fig. 2

A schematic description of the measurement of in vivo activity of ABO antibodies using complement-dependent cytotoxicity. Hemolysis is measured through free hemoglobin measurement of supernatants using an ultraviolet spectrophotometer.

ABO ANTIBODY MONITORING AFTER TRANSPLANTATION

The accommodation phenomenon, in which rejection does not occur even if the ABO antibody concentration increases, can occur 2–4 weeks after ABO-incompatible transplantation. Various theories have been suggested to explain this phenomenon: (1) the inhibition of complement and apoptosis; (2) no T-cell-dependent B-cell response; (3) blood group chimerism or shift; and (4) B-cell tolerance [5]. Thus, the clinical significance of measuring the ABO antibody level after accommodation has not yet been accurately established, and the Korean health insurance system covers ABO antibody measurements only up to 2 weeks after transplantation. The British Society for Haematology guidelines also state that there is no issue with transfusion of blood components of the patient’s blood type 4 weeks after transplant [23].

However, there was a case in which the ABO antibody titer increased rapidly due to sepsis, resulting in graft rejection several months after transplantation [24]. In this regard, it has been hypothesized that primary sensitization occurs due to ABO-associated antigens. The properties of antibody-mediated rejection (AMR) immediately after surgery and delayed AMR, which usually occurs 2 to 4 weeks after transplantation, are different, and in the latter type of AMR, there is a greater increase of the IgM titer than of the IgG titer [25]. Further studies are needed to elucidate the underlying mechanism.

CONCLUSIONS

The accurate measurement of ABO antibodies is essential for successful ABO-incompatible transplantation. The conventional titration method is considered standard and is applied in most laboratories. Various measurement methods have been developed, and new methods continue to be introduced. Each method has advantages and disadvantages. Therefore, physicians and laboratory specialists who are involved in ABO-incompatible transplantation need to fully understand these methods for optimal patient management.

HIGHLIGHTS
The accurate measurement of ABO antibodies is essential for successful ABO-incompatible solid organ transplantation. Titration has been used for a long time, but has many limitations. Physicians should be aware of the characteristics of ABO antibody testing methods for successful transplantation.